Melkart Duo

Metformin Hydrochloride and Vildagliptin, the active ingredient in Melkart Duo, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults.

GNH USA supplies Melkart Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melkart Duo is an oral antidiabetic combination used to improve glycaemic control in type 2 diabetes.

Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels when diet and exercise alone are insufficient. Adjunct to insulin therapy: provides additional glucose‑lowering effect in patients requiring insulin. Combination with lifestyle measures: supports weight management and insulin sensitivity as part of a comprehensive treatment plan.

Common Side Effects: - Gastrointestinal upset (nausea, diarrhoea, abdominal discomfort) - Headache or dizziness - Mild hypoglycaemia, especially when combined with other glucose‑lowering agents - Metallic taste or loss of appetite - Upper respiratory tract infection symptoms

Serious or Rare Side Effects: - Lactic acidosis (metformin‑related) - Severe hypersensitivity reactions, including angio‑edema or Stevens‑Johnson syndrome - Acute pancreatitis (vildagliptin‑related) - Hepatic dysfunction or failure

Before initiating therapy, evaluate renal and hepatic function and consider patient‑specific risk factors.

Renal function: assess eGFR and avoid use in severe renal impairment. Lactic acidosis risk: contraindicated in patients with significant renal or hepatic disease. Hypoglycaemia risk: monitor closely when combined with insulin or sulfonylureas. Pregnancy and lactation: use only if potential benefit justifies potential risk. Alcohol consumption: limit intake to reduce risk of lactic acidosis. Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Metformin and Vildagliptin may interact with several medicines that affect glucose control or renal clearance.

Major Interactions (Avoid): - Concomitant use of iodinated contrast agents in patients with reduced renal function. - Co‑administration with other biguanides (e.g., phenformin) – increased lactic acidosis risk. - Strong CYP2C9 inhibitors (e.g., fluconazole) that raise vildagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Sulfonylureas – heightened hypoglycaemia potential. - Insulin – additive glucose‑lowering effect. - Diuretics – may reduce metformin renal clearance. - Corticosteroids – may increase blood glucose, requiring dose adjustment.